DUSP1/MKP1 is a dual-specific phosphatase that regulates MAPKs activity, with an increasingly recognized role in tumor biology. To understand more about the involvement of DUSP1 in lung cancer, we performed gene expression analyses of parental and DUSP1-interfered H460 non-small-cell lung cancer (NSCLC) cells. Downregulation of DUSP1 induced changes in the expression levels of genes involved in specific biological pathways, including angiogenesis, MAP kinase phosphatase activity, cell-cell signaling, growth factor and tyrosine-kinase receptor activity. Changes in the expression of some of these genes were due to modulation of c-Jun-N-terminal kinase and/or p38 activity by DUSP1. Complementary functional assays were performed to focus on the implication of DUSP1 in angiogenesis and metastasis. In H460 cells, interference of DUSP1 resulted in a diminished capacity to invade through Matrigel, to grow tumors in nude mice and also to induce metastasis through tail-vein injection. Furthermore, the angiogenic potential of H460 cells was also impaired, correlating with a decrease in VEGFC production and indicating that DUSP1 could be required to induce angiogenesis. Finally, we studied whether a similar relationship occurred in patients. In human NSCLC specimens, DUSP1 was mainly expressed in those tumor cells close to CD31 vascular structures and a statistically significant correlation was found between VEGFC and DUSP1 expression. Overall, these results provide evidence for a role of DUSP1 in angiogenesis, invasion and metastasis in NSCLC.
DUSP1/MKP1 is a dual-specific phosphatase that regulates MAPKs activity, with an increasingly recognized role in tumor biology. To understand more about the involvement of DUSP1 in lung cancer, we performed gene expression analyses of parental and DUSP1-interfered H460 non-small-cell lung cancer (NSCLC) cells. Downregulation of DUSP1 induced changes in the expression levels of genes involved in specific biological pathways, including angiogenesis, MAP kinase phosphatase activity, cell-cell signaling, growth factor and tyrosine-kinase receptor activity. Changes in the expression of some of these genes were due to modulation of c-Jun-N-terminal kinase and/or p38 activity by DUSP1. Complementary functional assays were performed to focus on the implication of DUSP1 in angiogenesis and metastasis. In H460 cells, interference of DUSP1 resulted in a diminished capacity to invade through Matrigel, to grow tumors in nude mice and also to induce metastasis through tail-vein injection. Furthermore, the angiogenic potential of H460 cells was also impaired, correlating with a decrease in VEGFC production and indicating that DUSP1 could be required to induce angiogenesis. Finally, we studied whether a similar relationship occurred in patients. In human NSCLC specimens, DUSP1 was mainly expressed in those tumor cells close to CD31 vascular structures and a statistically significant correlation was found between VEGFC and DUSP1 expression. Overall, these results provide evidence for a role ofIntroduction Mitogen-activated protein kinases (MAPK) constitute a family of proteins transducing extracellular signals to effectors that control different cellular processes such as proliferation, differentiation, migration and apoptosis (Davis, 2000; Chang and Karin, 2001; Pearson et al., 2001; Johnson and Lapadat, 2002; Wada and Penninger, 2004) . The mechanisms of MAPK activation include phosphorylation on tyrosine and threonine residues of a conserved motif T-X-Y within the activation loop of the kinase. This process is mediated by a dual-specific MAPK kinase (MKK or MEK) that is regulated by a MAPK kinase-kinase. Three families of MAPK have been characterized in mammalian cells, which are differentially regulated in response to specific stimuli and present different substrate specificity. The three families are: ERK1 and ERK2, the c-Jun-N-terminal kinases (JNKs) 1, 2 and 3 and the p38 family of kinases (a, b, d and g). The intensity and long-lasting effect of MAPK signaling is regulated by a family of dual-specific MAP kinase phosphatases. This family of proteins constitutes a separate group within the cystein-dependent dual specificity protein phosphatases. On the basis of sequence similarity, gene structure, substrate specificity and subcellular location; this family can be subdivided into three different groups. The first group contains DUSP1/MKP1, DUSP2/Pac1, DUSP4/MKP2 and DUSP5/hVH3. The second group consists of DUSP6/MKP3, DUSP7/MKPX and DUSP9/MKP4. The final group comprises DUSP8/hVH5, DUSP10/ MKP5 and DUSP16/MKP7 (Keyse, 2008) .
The biochemical properties and the catalytical activities of most of these enzymes are well known, but their physiological function in normal cells and their role in pathologies such as cancer still remain unclear. DUSP1 is a nuclear mitogen and stress-inducible MAP kinase phosphatase highly expressed in different types of human tumors, including non-small-cell lung cancer (NSCLC), breast, ovarian, bladder, osteosarcoma and in prostate cancer in early stages of disease (Loda et al., 1996; Denkert et al., 2002; Chattopadhyay et al., 2006) . We have previously demonstrated that DUSP1 has an essential function in NSCLC biology (Chattopadhyay et al., 2006) , both in tumor growth and in response to cisplatin treatment. NSCLC cells expressing a smallinterfering RNA (siRNA) specific for DUSP1 were more sensitive to cisplatin and grew more slowly when injected into nude mice. Chemical compounds that inhibit DUSP1 expression also induce higher sensitivity to cisplatin (Chattopadhyay et al., 2006) . These results suggested that DUSP1 is an important target for tumor regression and understanding its function might lead to improvements in cell-death promoting chemotherapy.
One of the most important problems in the clinical outcome of NSCLC, which accounts for 80% of lung cancer, is the high percentage of patients that recur. Although new therapies have appeared in the treatment of locally advanced disease, the outcome of these treatments in the patients is very poor. The capacity of tumor cells to induce angiogenesis and lymphangiogenesis may increase the probability of haematogenous or lymphatic metastasis (He et al., 2002) . In lung cancer models, high levels of VEGFC directly promotes both tumor lymphangiogenesis and tumor dissemination to the regional lymph nodes (He et al., 2005) that can be blocked by inhibiting VEGFR3 signaling (He et al., 2002) . In addition, in NSCLC patients, increased expression of VEGFC, VEGFD and VEGFR3 are associated with a lower survival rate (Renyi-Vamos et al., 2005) . Furthermore, NSCLC metastasis correlates with angiogenesis and lymphangiogenesis. In the absence of vascular angiogenesis, NSCLC cells invade host lymphatics during tumor development (Renyi-Vamos et al., 2005) .
To gain insight into the cellular pathways involving DUSP1 actions in tumor progression we have used a double strategy that combines microarray and siRNA technology. This strategy provided a differential expression profile of genes functionally related to DUSP1. Here, we report that downregulation of DUSP1 expression in the NSCLC cell line H460 induces changes in the expression levels of other DUSPs and in other genes involved in tumor progression and angiogenesis maybe as a result of modulation of JNK/p38 activity. Cells expressing DUSP1-siRNA presented a reduction in their migratory, invasive and angiogenic potential, which translated into a reduced capacity of forming tumors in nude mice and metastatic dissemination. Moreover, in patients with NSCLC tumors expressing high levels of DUSP1, increase in VEGFC levels was also detected. These results suggest that blockage of DUSP1 expression in NSCLC would be a good strategy to inhibit both tumor vascularization and metastasis, and therefore would be a suitable strategy to block tumor progression.
Results
Identification of genes differentially expressed in parental control versus DUSP1-deficient H460 lung cancer cells We have previously reported that expressing DUSP1-siRNA in H460 cells (H460cri) (Chattopadhyay et al., 2006) resulted in earlier phosphorylation of JNK and p38 in response to CDDP and differences in tumor growth. Thus, changes in gene expression controlled by both kinases could underlie this observation. Therefore, we analyzed the changes in expression of 47 000 genes in H460cri cells compared with the H460v cell line (H460pSuperRetro vector). We found 136 genes with altered expression by at least threefold comparing both cell lines. Posterior gene ontology (GO) analysis identified, 45 GO categories with significantly enriched (Po0.01) gene numbers in the selected 136 genes compared with a reference gene set. These GO categories included cancer-relevant biological pathways, such as angiogenesis, MAP kinase phosphatase activity, cell-cell signaling, growth factor activity and tyrosinekinase receptor activity, among other pathways (Table 1) . Figure 1a ; Supplementary Figure 1) . To confirm that changes in gene expression in H460cri cells were indeed due to a decrease in DUSP1 expression, we reexpressed DUSP1 in H460cri cells (H460cripLXSNDUSP1) by using the retroviral vector pLXSNDUSP1 and estimated the expression levels of the above selected genes (Figure 1b) . The results showed a significant recovery of DUSP6, SH2D2A and VEGFC levels, suggesting that their expression is modified in response to DUSP1. However, NRP1 and BMP2 DUSP1 participates in tumor progression in NSCLC V Moncho-Amor et al expression were not significantly reduced after DUSP1 overexpression, and consequently we interpreted that it might be implicated in cancer progression, although not directly regulated by DUSP1. As DUSP1 targets JNK and p38, we overexpressed both kinases in H460v cells to check if changes in expression of the above indicated genes may be reproduced by expression of these kinases. We transiently expressed, JNK1 and p38a in H460v cells and levels of DUSP6, BMP2, SH2D2A2, VEGFC and NRP1 expression were measured by q-PCR. The results showed ( Figure 1c ) that expression levels of the genes were inhibited, and with small differences the results were equivalent for both kinases. These changes were similar to those observed in H460cri cells, indicating that one or both kinases could be responsible for the observed changes.
As the sequence of DUSP6 promoter has recently been reported (Ekerot et al., 2008; Morrison et al., 2008) , we investigated if DUSP1 was able to modulate DUSP6 expression by stimulating the promoter activity. Co-transfection of a DUSP6 promoter reporter vector (Prom DUSP6) and CTAPDUSP1, a strong and transient DUSP1 expression vector in 293T and H460 cells, induced the activation of DUSP6 by threefold and 1.5-fold, respectively (Figure 1d ). Furthermore, we cotransfected a DUSP1siRNA (Chattopadhyay et al., 2006) (DUSP1pSuper) construct able to target the CTAPDUSP1 expressed gene in H460v, and observed that it induced a decrease in the DUSP6 promoter activity at same levels as in H460cri cells, indicating that DUSP1 was indeed involved in the DUSP6 expression regulation (Figure 1d; Supplementary Figure 2) . Further, we transiently overexpressed DUSP1 in H460v and H460cri cells with the CTAPDUSP1 expression vector and found a higher basal activation of DUSP6 promoter in H460v-transfected cells when compared with the basal activation observed in H460cri-transfected cells (Figure 1e ). In addition, H460cri cells stably reexpressing DUSP1 (Figure 1b , H460cripLXSN-DUSP1) (Figure 1e , H460cri o.e. DUSP1) showed a higher activation of DUSP6 promoter when compared with H460cri cells (Figure 1e) indicating that although the DUSP1 coding sequence of this expression vector is sensitive to siRNA, it can still overcome the effects of DUSP1siRNA when overexpressed. Therefore, in all situations, transfection of the DUSP1 expression vector was able to increase activation of DUSP6 promoter.
Inhibition of DUSP1 expression limits cell motility and invasion of NSCLC cells As our GO analysis selected genes involved in extracellular matrix formation and cell invasion, we proceeded to evaluate cell-migratory capacity of H460v and H460cri cells by the wound-healing assay. In 24 h, parental H460v cells healed the wounded area (9% distance left), whereas H460cri cells were unable to do so in the same time period (46% distance left) and these results were statistically significant (Po0.001) (Figure 2a ). The growth capacity of both cells lines, measured by a standard growth assay in complete medium, was similar ( Figure 2b) ; hence, the differences were due to motility and not to growth. As we observed above that expression of JNK or p38a could induce changes in gene expression in H460v cells similar to those in H460cri cells (Figure 1c) , we investigated if these were also related to changes in cell motility. H460v cells were transfected with JNK1 or p38a, and the results showed (Figure 2c ) that H460v cells transfected with empty vector healed the wounded area with 66% distance left, whereas cells transfected with either JNK or p38a, were slower in the same period of time (77 and 75% distance left, respectively), and these results were statistically significant.
To investigate possible differences in invasiveness, an in vitro Matrigel invasion assay was performed using H460v and H460cri cells. H460v displayed larger invasive capacity than H460cri cells (67±4 versus 15 ± 1 number of invading cells) (Figures 2d and e) . These results suggest that DUSP1 is involved in maintaining migratory and invasive capacity of H460 cells.
DUSP1 modulates angiogenesis in H460 cells
During tumor progression, tumor cells acquire the ability to activate the expansion of surrounding blood vessels by not fully a characterized mechanisms (Carmeliet, 2005) . As H460cri cells showed an important decrease in VEGFC and SH2D2A mRNA expression, we compared the angiogenic potential of conditioned media (CM) obtained from H460v and H460cri cells on migration of human microvascular endothelial cells. CM prepared from H460v cells was fourfold more potent than H460cri CM in the induction of human microvascular endothelial cells migration (Figure 3a) . These results indicated that DUSP1 interference generated signals that significantly impaired the secretion of proangiogenic factors, leading to a reduced migration of human microvascular endothelial cells. We then evaluated the angiogenic potential of H460v and H460cri cells CM using an in vivo angiogenesis assay. CM from either cell line was included in Matrigel plugs and implanted subcutaneously into the flanks of nude mice. Vascularization of the plugs was evaluated by immunohistochemistry using a specific antibody for endothelial cells: anti-Von Willebrand factor (Figure 3b ). These results demonstrate that DUSP1 silencing significantly impairs the capacity of H460 cells to promote new vessel formation, and therefore interference of DUSP1 expression acts as angiogenic inhibitor.
DUSP1 controls tumorigenicity and metastasis in H460 cells
As expression of some genes involved in growth factor activity and cell signaling (Table 1) was lower in H460cri cells, we studied the efficiency of these cells to induce DUSP1 participates in tumor progression in NSCLC V Moncho-Amor et al tumors in nude mice. The tumorigenic capacity and tumors volume were reduced in 30 and 50%, respectively using H460cri compared with H460v cells (Figure 4a ).
As we described above that H460cri cells have a reduced angiogenic potential compared with H460v cells, we aimed to investigate its impact on tumor growth. We studied the microvascular density in H460-, H460v-and H460cri-induced tumors (Figures 4b and d; Supplementary Figure 3) and found that H460cri tumors presented a significant reduction in anti-CD31 positive vessels in agreement with previous results, suggesting that tumor growth may be impaired in H460cri cell-derived tumors due, at least in part, to impaired angiogenesis. We finally estimated if, in agreement with the data obtained in the array studies, tumors derived from H460, H460v and H460cri cells presented significant differences in VEGFC and found Figure 1 and 24 h later assayed for wound-healing assays. The table represents the distance between both edges of the wound in each transfected cell line (10 random measures/each cell line) for three independent experiments, Po0.001 was considered a significant change in cell migration (Student's t-test). (d) HT-1080, MCF7, H460v and H460cri cells were used to test the cell invasiveness using Biocoat Matrigel invasion chambers. HT-1080 and MCF7 were used as positive and negative control, respectively. Data represents number of cells invading the lower chamber after 24 h for each cell line. A total of 10 random fields for each membrane were pictured ( Â 20 magnification) and quantified for three independent experiments. (e) Representative micrographs of H460v and H460cri invading cells, taken at the bottom surface of the filter.
DUSP1 participates in tumor progression in NSCLC
V Moncho-Amor et al that expression levels of VEGFC in H460cri tumors were significantly lower than that observed in H460v tumors (Figures 4c and e) and this may contribute to observed variations in the vascularization degree of tumors generated from these cell lines. As both tumor cell migration and angiogenic potential were reduced in H460cri cells, we investigated the capacity of these cells to metastasize using the tail-vein injection model. The anatomical examination showed that animals injected with H460v cells presented macroscopic tumors in lung, mediastinum, kidney and heart, and less frequently in brain, pancreas, diaphragm and suprarenal gland (Figure 5a, left panel) . In contrast, animals injected with H460cri cells showed tumors only in lung, and just in one case, in heart and suprarenal gland (Figure 5a, right panel) . In addition, the median survival time after injection was shorter for those animals injected with H460v than those injected with H460cri cells (P ¼ 0.006; hazard ratio 4.59) (Figure 4b) , correlating with the cells invasion capacity. The morphology of the primary tumors and the metastases generated both by H460v and H460cri cells were similar in all animals, showing an infiltration of visceral organs by whitish irregular nodules (Supplementary Figure 4a) constituted by a proliferation of atypical epithelial cells, arranged in solid sheets with scattered small glandular lumens and extensive necrosis (Supplementary Figure  4b) . The immunophenotype of tumor cells showed both epithelial (expression of AE1/AE3 cytokeratins) (Supplementary Figure 4c ) and mesenchymal differentiation (expression of vimentin) (Suplementary Figure 4d ) and the mitotic index was over 90% using the Ki67 marker (Supplementary Figure 4e) . The CD31 immunohistochemical analysis in the metastasized lungs of both cell lines revealed an important decrease in angiogenesis in metastasized lung by H460cri cells (Figure 5b) , further supporting the fact that lack of DUSP1 severely impairs angiogenesis and results in diminished metastatic potential.
Expression of VEGFC is increased in human NSCLC tumors with high level of DUSP1 expression
Our previous results strongly suggested that expression of VEGFC in NSCLC H460 cells was dependent on DUSP1 activity. Further, expression of DUSP1 also correlated with angiogenesis and metastasis using in vivo animal models. To investigate the relevance in NSCLC DUSP1 participates in tumor progression in NSCLC V Moncho-Amor et al patients, we first investigated the distribution of DUSP1 in tumors followed by the colocalization of the phosphatase and endothelial cells. The majority of tumor cells expressing high levels of DUSP1 were detected in the proximity of CD31-positive vascular structures (Figure 6a) . We then assessed the expression of DUSP1 and VEGFC in a series of NSCLC tumor samples. Colocalization by immunofluorescence and analysis of expression of both DUSP1 and VEGFC in NSCLC specimens indicated a significant correlation between both proteins (Figure 6b ). VEGFC was detected in only 17% of the neoplastic cells with undetected or low expression of DUSP1, whereas VEGFC was present up to 62% of cells expressing DUSP1 (P ¼ 0.002) (Figure 6c ). Collectively, these results support a direct correlation between DUSP1 expression and angiogenesis in human NSCLC.
Discussion
The physiological roles of many of the DUSPs are largely unknown in vivo. Many have shown differential expression in multiple types of human cancer. Overexpression of the ubiquitous DUSP1 has been found in 
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V Moncho-Amor et al several malignancies, including breast, prostate and NSCLC (Loda et al., 1996; Denkert et al., 2002; Chattopadhyay et al., 2006) . Lung cancer is a major cause of cancer mortality and accounts for about 20% of all cancer deaths worldwide. The complete map of mutations in lung cancer has been recently published (Ding et al., 2008) and some of them may trigger DUSP1 expression, as we have found an increase in DUSP1 expression in nearly 80% of NSCLC patient samples (Chattopadhyay et al., 2006) . Here, we described differences in gene expression profile in NSCLC cells, which have been depleted of DUSP1, including groups of genes related to cell growth, migration or angiogenesis. These genes were downregulated in the vast majority of cases, in cells lacking DUSP1. Although in this manuscript we have focused in the study of genes involved in angiogenesis and migration, the regulation of other genes nicely correlates with the phenotype of the NSCLC cell line H460cri when compared with H460v cells. Among these genes are: phosphoinositide-3-kinase regulatory subunit 1-a (PIK3R1) (À4.26 fold), which is a regulator of AKT/ PKB signaling pathway, is involved in cell survival and has been implicated in poor responses to chemotherapy in lung cancer (Downward, 2008; Marinov et al., 2009; Sos et al., 2009) ; dickkopf homolog-1 (DKK1) (À3.36 fold) , a potent antagonist of Wnt signaling, is expressed at high levels in lung and esophageal carcinomas (Yamabuki et al., 2007) and hepathocarcinomas (Yu et al., 2009) ; tissue-type plasminogen activator (PLAT) (À4.949 fold) has been previously found significantly downregulated in nonangiogenic NSCLC tumors as compared with angiogenic tumors (Offersen et al., 2007) , and therefore its downregulation in H460cri cells agrees with its reduced angiogenic potential; epidermal growth factor receptor (EGFR) (À3.29 fold) has been intensely studied, not only to understand the mechanisms underlying its oncogenic potential, but also to exploit as a therapeutic target (Hynes and MacDonald, 2009 ) as inhibition of its activity decreases lung cancer cell growth in tumors, which show mutated versions of this receptor. Finally, BMP2 has been found overexpressed in human NSCLC, with little or no expression in normal lung tissue or benign lung tumors, (Langenfeld et al., 2003) suggesting that BMP2 may enhance tumor progression. We found that BMP2 expression is downregulated after interfering DUSP1, supporting those results. In addition, inhibition of BMP2 results in a significant reduction of tumor growth (Langenfeld et al., 2003) . Our group described similar results DUSP1 participates in tumor progression in NSCLC V Moncho-Amor et al regarding DUSP1 actions (Chattopadhyay et al., 2006) and tumor growth, suggesting a possible interaction between DUSP1 and BMP2.
JNK and p38 are major targets for DUSP1 (Keyse, 2000 (Keyse, , 2008 Sanchez-Perez et al., 2000) and therefore inhibition of the activity of such kinases may mediate the observed changes in gene expression and cell behavior found in H460v cells as demonstrated when we expressed either JNK or p38a in H460v cells. As yet, p38 has been involved in repressing expression of EGFR in a p38a knockout model (Ventura et al., 2007) , in agreement with our results that demonstrated that inhibition of DUSP1 expression leads to a reduced EGFR mRNA levels.
Among the genes selected in our study, expression of DUSP6 increases when reexpresing DUSP1 in H460cri cells. Although it has been reported that ERK activity modulates DUSP6 expression in response to fibroblast growth factor (Ekerot et al., 2008) , in H460 cells expression of DUSP1 increases both DUSP6 promoter activation and expression, thus maybe other kinases, such as p38a and/or JNK, should control DUSP6 expression by repressing its promoter. DUSP6 can be upregulated in specific cancers exhibiting aberrant RTK and ras/raf signaling such as NSCLC (Sato et al., 2006) . In this context, DUSP6 promoter comprises two regions relevant for controlling its expression, which contains 4-Egr1 binding sites (Morrison et al., 2008) . EGR-1 is a transcriptional target of the EGFR signaling pathway (Nutt et al., 2007) and EGFR expression is downregulated by threefold in H460cri cells, which again indicated a high correlation between expression levels of DUSP6, activation of DUSP6 promoter and levels of DUSP1.
Our results indicate that upregulation of DUSP1 expression and consequently changes in JNK and p38 activities are involved in tumorigenesis and the control of invasion and metastasis in NSCLC cells. There is a relevant difference in tumor size between the tumors induced by H460v cells and those induced by H460cri cells, which might be related to the decreased levels of EGFR, PIK3R1 and MERTK (Ling and Kung, 1995) . Activation of MERTK in NIH3T3 fibroblasts led to cellular transformation (Ling and Kung, 1995) and activation of the RAS/PI3K pathway (Linger et al., 2008) .
The inhibition of VEGFC and SH2D2A expression by the inhibition of DUSP1 expression points up a possible role of this phosphatase-controlling tumor angiogenesis. In fact, in vivo and in vitro assays confirmed that the angiogenic potential of H460cri cells was significantly reduced compared with H460v cells. Moreover, we were able to demonstrate that tumors induced by H460cri cells showed reduced tumor size and lower levels of VEGFC, correlating with a decrease in tumor vascularization. Altogether the data indicate that DUSP1 profoundly affects the tumor capacity to properly vascularize.
In agreement with our results, DUSP1 has been reported as one of the 11 genes that cluster as a bone metastasis gene expression signature in breast cancer cells (Kang et al., 2003) . Using shRNA-mediated gene silencing in this cell system to knock down DUSP1 expression, a significant decrease in bone colonization was observed. The importance of DUSP1 in bone metastasis was clinically analyzed and found higher levels of DUSP1 in primary tumors of patients with bone metastasis (Lu et al., 2010) . Also in breast cancer, DUSP1 has been reported to be overexpressed in 50% of infiltrating breast carcinomas and to be an adverse prognostic factor for relapse by univariate and multivariate analyses in patients (Rojo et al., 2009) . We have observed a marked decrease in the metastatic potential of H460cri cells, correlating with a decrease in angiogenesis in the lung primary tumors, indicating that the diminished angiogenic potential of H460cri cells impairs tumor metastasis in this cell model. In summary, our results indicate that the overexpression of DUSP1 in NSCLC cells contributes to tumor growth, tumor invasion and angiogenesis. This control in the invasive phenotype seems to be mediated by expression changes of different genes probably due to changes in the activities of JNK and/or p38. Finally, in NSCLC specimens, we have found colocalization of DUSP1 expression and endothelial cells and also a strong correlation of DUSP1 expression and increased VEGFC expression, reinforcing the relevance of our findings for human cancer. Therefore, expression of DUSP1 in NSCLC should trigger angiogenesis as a result of increased expression of VEGFC. As a final point, our results suggest that inhibition of DUSP1 activity should be a good strategy to inhibit both tumor invasion and angiogenesis and also should represent a good candidate marker for combined treatment with chemotherapeutic drugs and angiogenic inhibitors in NSCLC.
Materials and methods

Cell lines, vector constructions and luciferase assay
The human NSCLC H460, human epithelial 293T/17, human fibrosarcoma connective tissue HT-1080 and human breast cancer adenocarcinoma MCF7 cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured as recommended. Primary human microvascular endothelial cells were cultured as described in Supplementary Material and Methods. The DUSP6 promoter luciferase, CTAPDUSP1, DUSP1pSuper vectors and control Renilla reporter were transfected into 293T, H460v and H460cri cells. The relative luciferase activity was determined using the DualLuciferase Reporter Assay System (Promega, Madrid, Spain). For more procedure details and vector constructions see Supplementary Material and Methods.
Microarray hybridization and gene selection Transcriptional profiling of H460v and H460cri was performed using Affymetrix HG-U133 plus 2.0 array (Affymetrix, Santa Clara, CA, USA) according to the Gene Chip Expression Analysis Technical Manual. Raw data were normalized with robust multichip average (RMA) and fold change between H460v and H460cri cells calculated. Data have been deposited in the NCBI's Gene Expression Omnibus, GEO (http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO series accession GSE19592. We selected a subset of genes for validation with at least threefold up-or downregulation in H460cri versus H460v cell lines, followed by the use of a Gene Ontology database as deeply described in Supplementary Material and Methods. As additional criteria, we chose those genes implicated in tumor progression, metastasis and angiogenesis within enriched GO categories that could be involved in biological pathways mediated by the DUSP1 and with a strong bibliographic support. Growth kinetic, wound-healing and in vitro invasion assays H460v and H460cri cells were grown in 24-well plates for the growth kinetic assay determination or in petri dish followed by a scratch to create the wound for the wound-healing assay. The relative distance traveled by the leading edge for 24 h was assessed using DS-L1 software (Nikon, New York, NY, USA). For the in vitro invasion assay, HT1080, MCF7, H460v and H460cri cell lines were seeded in serum-free medium in the upper chamber of the Biocoat Matrigel invasion chamber inserts (BD Biosciences, San Jose, CA, USA). Cells were allowed to invade through the Matrigel for 24 h using medium containing fetal bovine serum in the lower chamber as a chemoattractant. Following migration, cells were fixed and stained with Diff-Quick method (Medion Diagnostics, Miami, FL, USA) as recommended. Procedures are acutely described in Supplementary Material and Methods.
Tumorogenicity in xenograft mouse model H460v and H460cri cells were injected in both flanks from six nude mice. Tumor measurements were recorded as visible tumor appeared in 17 days after injection; and volume was calculated as l Â w 2 Â 0.52, where l is the length and w the width of the tumors. In a parallel experiment, mice were killed when tumor volume reached 50 mm 3 . Then, tumors were removed; one part was processed to measure microvascular density by CD31 inmunostaining as described above in the measurement of microvessels and the remaining tumor was formalin fixed and paraffin embedded to double check the CD31 immunostaining and to perform VEGFC expression analyses (H-score), which are deeply described in Supplementary Material and Methods.
Metastasis and survival assays Nude mice of 6 weeks were injected in the tail with H460v or H460cri cell suspension to compare their dissemination pattern and survival time. Animals were kept until death. Next, a complete necropsy examination of each animal was performed as already described (Espina et al., 2008) . Every visceral organ was formalin fixed and paraffin embedded in toto. Sections from each paraffin block were stained with hematoxylin and eosin to detect the presence of tumor metastatic foci in all the visceral organs. Representative sections were immunostained as described in Suplementary Material and methods. Statistical significance in survival time between H460v and H460cri cells in a total of 21 nude mice was also estimated according to the method of Kaplan-Meier; survival distributions were determined using the log-rank test. Po0.05 was considered to have statistical significance.
Colocalization by immunofluorescence assay
Immunofluorescence analysis of DUSP1, VEGFC and CD31 expression was performed on formalin-fixed and paraffinembedded tissue sections from human NSCLC specimens, and is exhaustively described in Supplementary Material and Methods. Two sets of sections were incubated with anti-DUSP1 and anti-CD31 antibodies or with anti-DUSP1 and anti-VEGFC antibodies. Sections were counterstained with 4 0 ,6-diamidino-2-phenylindole dihydrochloride (Vysis, Abbott Laboratories, Abbott Park, IL, USA) to visualize cell nuclei. Fluorescence in tumor cells was scored as percentage of the expression of VEGFC and DUSP1.
Abbreviations BMP2, bone morphogenetic protein 2; CDDP, Cisplatin; MERTK, c-mer proto-oncogene tyrosine kinase; PTPRK, protein tyrosine phosphatase receptor type K; VEGFC and D, vascular endothelial growth factor C and D; VEGFR3, vascular endothelial growth factor receptor3.
